bupropion and Amphetamine Abuse

bupropion has been researched along with Amphetamine Abuse in 26 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Research

Studies (26)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Change in Proportion of E-cigarettes Abstinent Days by Self-report at Stage 1

Proportion of abstinent days of E- Cigarettes was measured by self-report at stage 1. (NCT03078075)
Timeframe: Baseline, week 6

Change in Proportion of E-cigarettes Abstinent Days by Self-report at Stage 2

Proportion of abstinent days of E- Cigarettes was measured by self-report at stage 2. (NCT03078075)
Timeframe: week 7, week 12

Mean Change of Depression Symptom Score by PHQ-9 at Stage 1

"Patient Health Questionnaire-9 (PHQ-9) measures participants depression symptoms. Possible scores range from 0-27, with higher scores indicating a more severe depression symptoms.~PHQ-9 scores reflect depression severity, ranges from 0-27 (0 no depressive symptoms, 1-4 minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, 20-27 severe depression)" (NCT03078075)
Timeframe: Baseline, week 6

Mean Change of Depression Symptom Score by PHQ-9 at Stage 2

"Patient Health Questionnaire-9 measures participants depression symptoms. Possible scores range from 0-27, with higher scores indicating a more severe depression symptoms.~PHQ-9 scores reflect depression severity, ranges from 0-27 (0 no depressive symptoms, 1-4 minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, 20-27 severe depression)" (NCT03078075)
Timeframe: week 7, week 12

Mean Change of Methamphetamine Craving at Stage 1

Severity of methamphetamine craving, as measured by Visual Analog Craving Scales (VAS), during the treatment period. VAS scores range from 0 (no craving) to 100 (most intense craving possible). The VAS is completed at screening, once a week during the treatment period, and at the follow-up visits. (NCT03078075)
Timeframe: Baseline, week 6

Mean Change of Methamphetamine Craving at Stage 2

Severity of methamphetamine craving, as measured by Visual Analog Craving Scales (VAS), during the treatment period. VAS scores range from 0 (no craving) to 100 (most intense craving possible). The VAS is completed at screening, once a week during the treatment period, and at the follow-up visits. (NCT03078075)
Timeframe: week 7, week 12

Mean Change of Overall Functioning as Measured by Treatment Effectiveness Assessment (TEA) at Stage 1

"The Treatment Effectiveness Assessment is a 4-item self-administered assessment that uses a Likert scale (1-10) to document changes in four life domains: substance use, health, lifestyle, and community and is collected at screening, mid-treatment (Week 6 Visit 2) and end-of-treatment (Week 12 Visit 2).~Possible scores range from 4-40, with higher scores indicating a higher overall functioning." (NCT03078075)
Timeframe: Baseline, week 6

Mean Change of Overall Functioning as Measured by Treatment Effectiveness Assessment (TEA) at Stage 2

"The Treatment Effectiveness Assessment is a 4-item self-administered assessment that uses a Likert scale (1-10) to document changes in four life domains: substance use, health, lifestyle, and community and is collected at screening, mid-treatment (Week 6 Visit 2) and end-of-treatment (Week 12 Visit 2).~Possible scores range from 4-40, with higher scores indicating a higher overall functioning." (NCT03078075)
Timeframe: week 7, week 12

Mean Change of Percentage of Methamphetamine Abstinent Days Measured by Self-report at Stage 1

"Methamphetamine use selfreported on TLFB ( Timeline Followback) during the follow-up period.~The baseline measure is the percentage of abstinent days in the 30 days prior to randomization. The outcome is the change in percentage of abstinent days." (NCT03078075)
Timeframe: Baseline, week 6

Mean Change Percentage of Methamphetamine Abstinent Days Measured by Self-report at Stage 2

"Methamphetamine use selfreported on TLFB ( Timeline Followback) during the follow-up period.~The baseline measure is the percentage of abstinent days in the 30 days prior to randomization. The outcome is the change in percentage of abstinent days." (NCT03078075)
Timeframe: week 7, week 12

Mean Maximum Number of Consecutive Visits Negative UDS at Stage 1

Measured by maximum consecutive negative UDS: Count the number and range 0-12 and report the maximum number. (NCT03078075)
Timeframe: At week 6

Mean Maximum Number of Consecutive Visits Negative UDS at Stage 2

Measured by maximum consecutive negative UDS: Count the number and range 0-12 and report the maximum number. (NCT03078075)
Timeframe: Stage 2 evaluation period at Weeks 12

Mean Number of Study Weeks With Two Methamphetamine-negative UDS at Stage 1

Measured by the number of study weeks during the treatment period with two methamphetamine-negative UDS. (NCT03078075)
Timeframe: At week 6

Mean Number of Study Weeks With Two Methamphetamine-negative UDS at Stage 2

Measured by the number of study weeks during the treatment period with two methamphetamine-negative UDS. (NCT03078075)
Timeframe: At week12

Number of Participants Who Completed the Visit in Week 12

(NCT03078075)
Timeframe: At week 12

Percentage of Participants Who Used Methamphetamine in the Pre-evaluation Period

Methamphetamine use, as measured by UDS (urine drug screen) in the pre-evaluation period (Weeks 1-4 for Stage 1 and Weeks 7-10 for Stage 2 ) (NCT03078075)
Timeframe: Weeks 1-4 and Weeks 7-10

Treatment Effectiveness Score of Participants at Stage 1

The Treatment Effectiveness Score (TES) as measured by UDS results, during the treatment period. The TES is the percentage of the expected urine drug screens that were negative for each drug. Twelve urine drug screens are expected within each stage. (NCT03078075)
Timeframe: At weeks 6

Treatment Effectiveness Score of Participants at Stage 2

The Treatment Effectiveness Score (TES) as measured by UDS results, during the treatment period. The TES is the percentage of the expected urine drug screens that were negative for each drug. Twelve urine drug screens are expected within each stage. The range of possible scores are 0-100 and higher score indicates better outcomes. (NCT03078075)
Timeframe: At week 12

Mean Change in Number of Other Substance Use by Self-report at Stage 1

Number of other substance (Alcohol and Cigarettes) use was measured by self-report recall on Timeline Followback (TLFB) during the treatment period. (NCT03078075)
Timeframe: Baseline, week 6

Mean Change in Number of Other Substance Use by Self-report at Stage 2

Number of other substance (Alcohol and Cigarettes) use was measured by self-report recall on Timeline Followback (TLFB) during the treatment period. (NCT03078075)
Timeframe: week 7, week 12

Mean Change of Proportion of Other Substance Abstinent Days Measured by Self-report at Stage 1

Proportion of abstinent days of other substance including Alcohol, Cigarettes and E- Cigarettes was measured by self-report on TLFB during the treatment period. (NCT03078075)
Timeframe: Baseline, week 6

Mean Change of Proportion of Other Substance Abstinent Days Measured by Self-report at Stage 2

Proportion of abstinent days of other substance including Alcohol, Cigarettes and E- Cigarettes was measured by self-report on TLFB during the treatment period. (NCT03078075)
Timeframe: week 7, week 12

Mean Change of Quality of Life (QOL) by PhenX Core Tier 1 Instrument at Stage 1

Mean change score of QOL (General health, Physical health, and Mental health) from baseline will be assessed by PhenX (Phenotypes and eXposures) Core Tier 1 instrument: Quality of Life (QOL), which measures participants' quality of life during the past 30 days. Possible scores range from 0 to 30 (number of days in the past 30 in which health was good), with higher scores indicating a better quality of life. (NCT03078075)
Timeframe: Baseline, Week 6

Mean Change of Quality of Life (QOL) by PhenX Core Tier 1 Instrument at Stage 2

Mean change score of QOL (General health, Physical health, and Mental health) from baseline will be assessed by PhenX Core Tier 1 instrument: Quality of Life (QOL), which measures participants' quality of life during the past 30 days. Possible scores range from 0 to 30 (number of days in the past 30 in which health was good), with higher scores indicating a better quality of life. (NCT03078075)
Timeframe: week 7, week 12

Mean Number of Abstinent Days of Participants Who Used Other Substance Measured by UDS at Stage 1

Other substance use including Amphetamine, Non-Methamphetamine Drug, Cocaine, Alcohol, Cigarettes, as measured by UDS, during the treatment period. Opioid use will also be assessed using the Opioid 2000 ng tests on the UDS. (NCT03078075)
Timeframe: At week 6

Mean Number of Abstinent Days of Participants Who Used Other Substance Measured by UDS at Stage 2

Other substance use including Amphetamine, Non-Methamphetamine Drug, Cocaine, Alcohol, Cigarettes, as measured by UDS, during the treatment period. Opioid use will also be assessed using the Opioid 2000 ng tests on the UDS. (NCT03078075)
Timeframe: at week 12

Four Week Continuous Smoking Abstinence

A combination of daily self-reported smoking data and weekly carbon monoxide levels were used to determine continuous abstinence during post-quit days 15 - 42. (NCT01077024)
Timeframe: Post-quit days 15-42

Point-prevalence Abstinence (Smoking Outcome)

point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm (NCT01077024)
Timeframe: Week 10 assessment

Point-prevalence Abstinence (Smoking Outcome) 3 Month Visit

point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm (NCT01077024)
Timeframe: 3- month follow-up visits

Point-prevalence Abstinence (Smoking Outcome) 6 Month Visit

point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm (NCT01077024)
Timeframe: 6 month visit

Stimulant-free Results at 3-month Visit

At the 3-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back. (NCT01077024)
Timeframe: 3-month follow-up visit

Stimulant-free Results at 6-month Visit

At the 6-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back. (NCT01077024)
Timeframe: 6 - months follow-up visit

Stimulant-free Weeks Assessed by Self-report and Twice-weekly Urine Drug Screens

Stimulant-free week results (no cocaine, methamphetamine and amphetamine use) were obtained by combining the urine drug screens (UDS) and the self-reported Timeline Follow-Back (TLFB). At the group level, this outcome translates into the percentage of weeks in each study arm that are stimulant-free. (NCT01077024)
Timeframe: Week 16

End of Treatment Methamphetamine Abstinence

(NCT00833443)
Timeframe: 12 weeks

End of Treatment Methamphetamine Abstinence

Methamphetamine abstinence confirmed via urine drug screens during the final two weeks of treatment (weeks 11 and 12) (NCT00833443)
Timeframe: 12 weeks

Treatment Effectiveness Score

The mean number of methamphetamine-free urine drug screens provided by participants in each group (range 0-36) (NCT00833443)
Timeframe: 12 weeks

Treatment Retention

(NCT00833443)
Timeframe: 12 weeks

Number of Subjects Showing Abstinence

The primary efficacy outcome measure was a measurement of treatment success or failure, where a subject who successfully achieved two weeks of abstinence during the last two weeks of investigational product dosing (Weeks 11 and 12) was scored as a success. (NCT00687713)
Timeframe: Weeks 11 and 12

Treatment Success Among Subjects With 18 or Less Days of Methamphetamine Use

The study population for this outcome measure is defined as those participants with methamphetamine dependence who report using methamphetamine 18 or less days during the 30 days prior to signing consent. (NCT00687713)
Timeframe: 30 days

Acceptability: Adherence to Daily Bupropion and Placebo, as Determined by MEMS (Medication Event Monitoring System) Caps Openings

Proportion of days in which the MEMS cap device was opened during of the 12 weeks on study drug. (NCT00318409)
Timeframe: 12 weeks

Acceptability: Adherence to Daily Bupropion and Placebo, as Determined by Self-report

Proportional of reported days taking study drug during the 12 weeks of study. (NCT00318409)
Timeframe: 12 weeks

Acceptability: Proportion of Participants Discontinuing Medication in Both Arms

Proportion of participants who discontinued study medication for at least one week prior to study completion. (NCT00318409)
Timeframe: 12 weeks

Feasibility: Participants Who Completed the Trial

(NCT00318409)
Timeframe: 12 weeks

Feasibility: Proportion of Persons Screened Who Are Eligible and Enrolled

(NCT00318409)
Timeframe: At Enrollment

Feasibility: Proportion of Scheduled Study Visits Completed

(NCT00318409)
Timeframe: 12 weeks

Feasibility: Proportion of Urine Samples Collected

(NCT00318409)
Timeframe: 12 weeks

Tolerability: Comparison of Adverse Events in the Bupropion and Placebo Arms.

(NCT00318409)
Timeframe: throughout study

Cumulative Percent Adherence of Medication Events Monitoring (MEMs) Cap

To evaluate the adherence of lorcaserin vs. placebo, the investigators measured adherence as the frequency of taking the study drug as measured by the number of MEMS cap openings (wireless medication monitoring devices that record each opening as a real-time medication event). Cumulative percent adherence was calculated by dividing the frequency of openings at a given time point divided by the number of days since baseline. (NCT03192995)
Timeframe: 12 weeks

Mean Percentage of Weekly Follow-up Visits of Randomized Study Participants

To determine the feasibility of retaining individuals on lorcaserin vs. placebo, the investigators have calculated the mean weekly percentage of follow-up visits of those randomized in the study (NCT03192995)
Timeframe: 12 weeks

Proportion of Self-reported Past Week Cocaine Use Among Lorcaserin and Placebo Groups at Baseline and at 12 Weeks

The outcome measure determines the proportion of self-reported past week cocaine use by Time-Line-Follow-back (TLFB) among lorcaserin and placebo groups at Baseline and at 12 weeks. (NCT03192995)
Timeframe: 12 weeks

Proportion of Urine-positive Samples With Cocaine Positivity Among Lorcaserin and Placebo Groups at Baseline and at Week 12

The outcome measure determines the proportion of urine-positive samples with cocaine positivity among lorcaserin and placebo groups at Baseline and at Week 12 (NCT03192995)
Timeframe: Week 12

Reviews

2 reviews available for bupropion and Amphetamine Abuse

Trials

15 trials available for bupropion and Amphetamine Abuse

Other Studies

9 other studies available for bupropion and Amphetamine Abuse